New Protocols Under development - As of July 31 2026

Disease	Title/PI	Planned Activation
CTEP studies		
BN	**NRG-BN015:** Randomized phase 3 clinical trial of postoperative radiotherapy versus postoperative surveillance for clinical low-risk, molecular high-risk meningioma and longitudinal surveillance for clinical and molecular low-risk meningioma	Q4 2026
BN	**NRG-BN016:** Randomized Phase II Trial of Irradiation Alone Versus Irradiation Plus Abemaciclib in RB-Intact NRG High-Risk Meningioma (w/Safety lead-in)	Q1/Q2 2027
GI	**NRG-GI013:** Ablative Radiation Therapy To Liver Metastases For Immuno-Oncology (IO) Response in Microsatellite Stable (MSS) Colon Cancer (the RADIO study)	Q4 2026
GYN	**NRG-GY038:** A Phase II trial of sacituzumab govitecan (SG) and bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab in patients with platinum-sensitive ovarian cancer that has progressed on prior maintenance PARP inhibitor therapy	Q3 2026
GYN	**NRG-GY039**: A Phase III Non-Inferiority Trial of Hypofractionated Chemoradiation Therapy Versus Standard Chemoradiation for Cervical Cancer	Q1/Q2 2027
LU	**NRG-LU011:** A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer	Q4 2026
LU	**NRG-LU012**: A Randomized Phase 3 Study of Dose-Painted SBRT: A Study for Ultracentral Early-Stage NSCLC	Q2/Q3 2027
LU	**NRG-LU013: SORT:** A Randomized Phase II Study of **S**equencing **O**simertinib, **R**adiation, and Chemo**t**herapy in Stage III NSCLC with activating EGFR mutations.	Q2 2027
NCORP	**NRG-CC016**: ABCD RT Trial: Analysis of Biosignature Classification for DCIS Radiotherapy	Q3 2026